Opioid agonist and antagonist bivalent ligands as receptor probes

P. S. Portoghese; G. Ronsisvalle; D. L. Larson; C. B. Yim; L. M. Sayre; A. E. Takemori

doi:10.1016/0024-3205(82)90362-9

Opioid agonist and antagonist bivalent ligands as receptor probes

P. S. Portoghese, G. Ronsisvalle, D. L. Larson, C. B. Yim, L. M. Sayre, A. E. Takemori

Medicinal Chemistry

Research output: Contribution to journal › Article › peer-review

82 Scopus citations

Abstract

Bivalent ligands are molecules which contain two pharmacophores linked by a connecting chain (spanner). The present report describes the use of oxymorphamine (Oxy) and naltrexamine (Nal) as the opioid agonist and antagonist pharmacophores separated by a variable length spanner composed of succinyl-bis-oligoglycine. The agonist series, [CH₂CO(Gly)_nOxy]₂, and antagonist series, [CH₂CO(Gly)_nNal]₂, were synthesized (n = 0-4) and tested on the electrically stimulated GPI. All of the antagonist bivalent ligands (Nal) antagonized the effects of morphine, with the greatest potency enhancement (60 x) residing with the succinyl (n = 0) congener. A dramatically different SAR profile was observed in the agonist (Oxy) series where the greatest potency enhancement (17 x) occurs when n = 2. By contrast with the antagonist series the agonist bivalent ligand with n = 0 is equipotent to its monovalent agonist analogue. The significance of these results with respect to the possibility of discrete opioid agonist and antagonist recognition sites are discussed.

Original language	English (US)
Pages (from-to)	1283-1286
Number of pages	4
Journal	Life Sciences
Volume	31
Issue number	12-13
DOIs	https://doi.org/10.1016/0024-3205(82)90362-9
State	Published - Sep 1982

Publisher link

10.1016/0024-3205(82)90362-9

Find It

Find It at U of M Libraries

Cite this

@article{061933ac38c24a80ba0c8bf2cb5fbc6b,

title = "Opioid agonist and antagonist bivalent ligands as receptor probes",

abstract = "Bivalent ligands are molecules which contain two pharmacophores linked by a connecting chain (spanner). The present report describes the use of oxymorphamine (Oxy) and naltrexamine (Nal) as the opioid agonist and antagonist pharmacophores separated by a variable length spanner composed of succinyl-bis-oligoglycine. The agonist series, [CH2CO(Gly)nOxy]2, and antagonist series, [CH2CO(Gly)nNal]2, were synthesized (n = 0-4) and tested on the electrically stimulated GPI. All of the antagonist bivalent ligands (Nal) antagonized the effects of morphine, with the greatest potency enhancement (60 x) residing with the succinyl (n = 0) congener. A dramatically different SAR profile was observed in the agonist (Oxy) series where the greatest potency enhancement (17 x) occurs when n = 2. By contrast with the antagonist series the agonist bivalent ligand with n = 0 is equipotent to its monovalent agonist analogue. The significance of these results with respect to the possibility of discrete opioid agonist and antagonist recognition sites are discussed.",

author = "Portoghese, {P. S.} and G. Ronsisvalle and Larson, {D. L.} and Yim, {C. B.} and Sayre, {L. M.} and Takemori, {A. E.}",

year = "1982",

month = sep,

doi = "10.1016/0024-3205(82)90362-9",

language = "English (US)",

volume = "31",

pages = "1283--1286",

journal = "Life Sciences",

issn = "0024-3205",

publisher = "Elsevier Inc.",

number = "12-13",

}

TY - JOUR

T1 - Opioid agonist and antagonist bivalent ligands as receptor probes

AU - Portoghese, P. S.

AU - Ronsisvalle, G.

AU - Larson, D. L.

AU - Yim, C. B.

AU - Sayre, L. M.

AU - Takemori, A. E.

PY - 1982/9

Y1 - 1982/9

N2 - Bivalent ligands are molecules which contain two pharmacophores linked by a connecting chain (spanner). The present report describes the use of oxymorphamine (Oxy) and naltrexamine (Nal) as the opioid agonist and antagonist pharmacophores separated by a variable length spanner composed of succinyl-bis-oligoglycine. The agonist series, [CH2CO(Gly)nOxy]2, and antagonist series, [CH2CO(Gly)nNal]2, were synthesized (n = 0-4) and tested on the electrically stimulated GPI. All of the antagonist bivalent ligands (Nal) antagonized the effects of morphine, with the greatest potency enhancement (60 x) residing with the succinyl (n = 0) congener. A dramatically different SAR profile was observed in the agonist (Oxy) series where the greatest potency enhancement (17 x) occurs when n = 2. By contrast with the antagonist series the agonist bivalent ligand with n = 0 is equipotent to its monovalent agonist analogue. The significance of these results with respect to the possibility of discrete opioid agonist and antagonist recognition sites are discussed.

AB - Bivalent ligands are molecules which contain two pharmacophores linked by a connecting chain (spanner). The present report describes the use of oxymorphamine (Oxy) and naltrexamine (Nal) as the opioid agonist and antagonist pharmacophores separated by a variable length spanner composed of succinyl-bis-oligoglycine. The agonist series, [CH2CO(Gly)nOxy]2, and antagonist series, [CH2CO(Gly)nNal]2, were synthesized (n = 0-4) and tested on the electrically stimulated GPI. All of the antagonist bivalent ligands (Nal) antagonized the effects of morphine, with the greatest potency enhancement (60 x) residing with the succinyl (n = 0) congener. A dramatically different SAR profile was observed in the agonist (Oxy) series where the greatest potency enhancement (17 x) occurs when n = 2. By contrast with the antagonist series the agonist bivalent ligand with n = 0 is equipotent to its monovalent agonist analogue. The significance of these results with respect to the possibility of discrete opioid agonist and antagonist recognition sites are discussed.

UR - http://www.scopus.com/inward/record.url?scp=0020451569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020451569&partnerID=8YFLogxK

U2 - 10.1016/0024-3205(82)90362-9

DO - 10.1016/0024-3205(82)90362-9

M3 - Article

C2 - 6292615

AN - SCOPUS:0020451569

SN - 0024-3205

VL - 31

SP - 1283

EP - 1286

JO - Life Sciences

JF - Life Sciences

IS - 12-13

ER -

Opioid agonist and antagonist bivalent ligands as receptor probes

Abstract

Publisher link

Find It

Other files and links

Fingerprint

Cite this